Panavir, 0.04 mg/ml 5 ml 2 pcs

Pharmacotherapeutic group:

An antiviral and immunomodulatory agent.

ATX CODE: J05AX.

Pharmacological properties

.Pharmacodynamics

Panavir® is a purified extract of the shoots of the plant Solanum tuberosum; the main active ingredient is a hexose glycoside consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, uronic acids.

Panavir® is an antiviral and immunomodulatory agent. It increases nonspecific resistance to various infections and promotes induction of interferon alpha and gamma by blood leukocytes.

The drug is well tolerated in therapeutic doses.

Tests showed absence of mutagenic, teratogenic, carcinogenic, allergic and embryotoxic action. In preclinical studies on laboratory animals no negative effects on reproductive function and fetal development were found.

It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the test of pseudoallergic inflammatory response to concanavalin A.

The analgesic effect in models of neurogenic pain and pain caused by inflammation and thermal irritation is shown.

It has antipyretic effect.

In a model of parkinsonian syndrome caused by systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neuroprotective properties have been shown.

It has the ability to improve retinal and optic nerve function.

It has wound-healing properties in a gastric ulcer model.

Pharmacokinetics

In intravenous administration, polysaccharides are detected in the blood as early as 5 min after administration and are taken up by reticulo-endothelial cells of the liver and spleen. Excretion begins quickly, in 20-30 minutes polysaccharides are detected in urine and exhaled air.

Indications

• Herpesvirus infections of various localizations (including recurrent genital herpes, herpes zoster and ophthalmic herpes).
• Secondary immunodeficiency states due to infectious diseases.
• Cytomegalovirus infection, including in patients with recurrent miscarriage.
• Used in women with chronic viral infection and interferon deficiency in preparation for pregnancy.
• Chronic cytomegalovirus infection in the acute stage in pregnant women in the 2nd and 3rd trimester as part of complex therapy.
• Human papillomavirus infection (anogenital warts) as part of complex therapy.
• Peptic ulcer of the stomach and duodenum in patients with long-term scarring ulcers and symptomatic ulcers of the gastroduodenal zone as part of complex therapy.
• Tick-borne encephalitis to reduce the viral load and relieve neurological symptoms (anisoreflexia, decreased reflexes, pain at the exit points of cranial nerves, nystagmus) as part of complex therapy.
• Rheumatoid arthritis combined with herpesvirus infection in immunocompromised patients (to enhance the analgesic and anti-inflammatory effect of the main therapy), as part of complex therapy.
• ARVI and influenza as part of complex therapy.
• Panavir® is used in complex therapy of chronic bacterial prostatitis.

Pharmacological effect

PHARMACOTHERAPEUTIC GROUP:

Antiviral and immunomodulatory agent.

ATX CODE: J05AX.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

Panavir® – purified extract of shoots of the Solanum tuberosum plant; the main active ingredient is a hexose glycoside consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, and uronic acids.

The drug Panavir® is an antiviral and immunomodulatory agent. Increases the body’s nonspecific resistance to various infections and promotes the induction of alpha and gamma interferons by blood leukocytes.

In therapeutic doses, the drug is well tolerated.

Tests have shown the absence of mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic effects. In preclinical studies on laboratory animals, no negative effects on reproductive function and fetal development were established.

It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the pseudoallergic inflammatory reaction test to concanavalin A.

An analgesic effect has been shown in models of neurogenic pain and pain caused by inflammation and thermal irritation.

Has an antipyretic effect.

In a model of parkinsonian syndrome caused by systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, neuroprotective properties were shown.

Has the ability to improve the functions of the retina and optic nerve.

It has wound-healing properties in a gastric ulcer model.

Pharmacokinetics

When administered intravenously, polysaccharides are detected in the blood within 5 minutes after administration and are captured by the cells of the reticuloendothelial system of the liver and spleen. Elimination begins quickly; after 20-30 minutes, polysaccharides are found in the urine and exhaled air.

Special instructions

When used in preparation for pregnancy, it helps reduce the frequency of reproductive losses due to cytomegalovirus and herpesvirus infections.
If the solution becomes cloudy, the drug is considered unsuitable for use.

INFLUENCE ON THE ABILITY TO DRIVE VEHICLES, MECHANISMS
There is no data on the possibility of a negative effect of the drug on the ability to drive vehicles and carry out potentially hazardous activities that require special attention and speed of psychomotor reactions.

Active ingredient

Potato shoots amount of polysaccharides

Composition

active substance – Panavir® (potato shoots sum of polysaccharides) – 200 mcg;

excipients: sodium chloride – 0.045 g, water for injection – up to 5 ml.

Pregnancy

Use is possible in the 2nd and 3rd trimester according to the indication of chronic cytomegalovirus infection in the acute stage as part of complex therapy. In other cases, use is possible only if the expected benefit to the mother outweighs the potential risk to the fetus. If it is necessary to use the drug during lactation, breastfeeding should be stopped while taking the drug.

Contraindications

• Individual intolerance. Panavir® should not be used by patients who are allergic to the constituent components of the drug: glucose, mannose, rhamnose, arabinose, xylose.
• Lactation period.
• Children under 12 years of age.

Side Effects

The drug is well tolerated, possible complications may be associated with individual intolerance and hypersensitivity to the components of the drug.

However, if any unwanted side effects occur, you should stop administering the drug and consult your doctor.
If you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Not registered.

Overdose

No cases of overdose have been reported. The results of preclinical studies indicate low toxicity of the drug.

Storage conditions

In a place protected from light, at a temperature of 2 to 25 ° C. Keep out of the reach of children.

Shelf life

5 years.
Do not use after the expiration date stated on the package.

Manufacturer

Ellara LLC, Russia